Regeneus and Kyocera ink lucrative deal to commercialise Progenza in $3.5 billion dollar market
Finfeed
Archived
Aug 11, 2020
Japan is an important market for clinical stage regenerative medicine company, Regeneus Ltd (ASX: RGS), which has just negotiated a license agreement with Kyocera Corporation (Kyocera, TYO:6971) to develop and commercialise Progenza for Knee Osteoarthritis (Progenza OA) in Japan.
